# Alfred H.J. Kim

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alfred-h-j-kim/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,701 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 34 |
| i10-index | 60 |
| Last Known Institution | Washington University in St. Louis |
| OpenAlex ID | https://openalex.org/A5032281507 |
| ORCID iD | 0000-0003-4074-0516 |
| Works | 153 |

## Researcher papers

- [Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies](https://scholariq.org/papers/resistance-of-sars-cov-2-variants-to-neutralization-by-monoclonal-and-serum/)
- [The complement system in COVID-19: friend and foe?](https://scholariq.org/papers/the-complement-system-in-covid-19-friend-and-foe/)
- [Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2](https://scholariq.org/papers/effect-of-immunosuppression-on-the-immunogenicity-of-mrna-vaccines-to-sars-cov-2/)
- [Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know](https://scholariq.org/papers/use-of-hydroxychloroquine-and-chloroquine-during-the-covid-19-pandemic-what/)
- [Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection](https://scholariq.org/papers/increased-complement-activation-is-a-distinctive-feature-of-severe-sars-cov-2/)
- [A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19](https://scholariq.org/papers/a-rush-to-judgment-rapid-reporting-and-dissemination-of-results-and-its/)
- [Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis](https://scholariq.org/papers/response-to-sars-cov-2-vaccination-in-immune-mediated-inflammatory-diseases/)
- [Cardiac Manifestations of Systemic Lupus Erythematosus](https://scholariq.org/papers/cardiac-manifestations-of-systemic-lupus-erythematosus/)
- [COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations](https://scholariq.org/papers/covid-19-in-people-with-rheumatic-diseases-risks-outcomes-treatment/)
- [<scp>SARS</scp>–<scp>CoV</scp>‐2 Infection and <scp>COVID</scp>‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis](https://scholariq.org/papers/scp-sars-scp-scp-cov-scp-2-infection-and-scp-covid-scp-19-outcomes-in-rheumatic/)
- [Belimumab for systemic lupus erythematosus – Focus on lupus nephritis](https://scholariq.org/papers/belimumab-for-systemic-lupus-erythematosus-focus-on-lupus-nephritis/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Long-Term Effects of COVID-19](https://scholariq.org/topics/long-term-effects-of-covid-19/)

## Researcher university

- [Washington University in St. Louis](https://scholariq.org/institutions/washington-university-in-st-louis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.